Malignant Pleural Mesothelioma

Raja, Siva; Murthy, Sudish C.; Mason, David P.

doi:10.1007/s11912-011-0177-9

Cited by 33 publications

(29 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is currently the deadliest cancer [5], but there have been considerable advances in the diagnosis and treatment of this disease that has led to an improvement of median survival in advanced-stage lung cancers from 7-8 months in 2000 [6] to 15 months in 2010 [7]. The incidence of mesothelioma is still increasing worldwide [8].…”

Section: @Erspublicationsmentioning

confidence: 99%

Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe

Gamarra¹,

Boffetta

Ruysscher³

et al. 2013

Eur Respir J

View full text Add to dashboard Cite

Section: @Erspublicationsmentioning

confidence: 99%

Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe

Gamarra¹,

Boffetta

Ruysscher³

et al. 2013

Eur Respir J

View full text Add to dashboard Cite

“…Human epithelioid mesothelioma cells, NCI-H226 (CRL-5826), and human biphasic mesothelioma cells, MSTO-211H M alignant pleural mesothelioma (MPM) affects the lung pleura and is a highly lethal cancer, with survival rates ranging from 4 to 17 months from diagnosis (1)(2)(3). MPM is primarily caused by the inhalation of asbestos fibers, which then settle in the lungs and become imbedded in the pleura, causing chronic inflammation that eventually leads to malignant transformation (1,3).…”

Section: Cell Lines and Tissue Culturementioning

confidence: 99%

Orthotopic Pleural Mesothelioma in Mice: SPECT/CT and MR Imaging with HER1- and HER2-targeted Radiolabeled Antibodies

Nayak

Bernardo²,

Milenic³

et al. 2013

Radiology

View full text Add to dashboard Cite

Purpose:To evaluate the potential of anti-human epidermal growth factor receptor (HER)1-and anti-HER2-targeted radiolabeled antibodies and magnetic resonance (MR) imaging for imaging of orthotopic malignant pleural mesothelioma (MPM) in mouse models. Materials and Methods:Animal studies with 165 mice were performed in accordance with National Institutes of Health guidelines for the humane use of animals, and all procedures were approved by the institutional Animal Care and Use Committee. Flow cytometry studies were performed to evaluate HER1 and HER2 expression in NCI-H226 and MSTO-211H mesothelioma cells. Biodistribution and single photon emission computed tomography (SPECT)/computed tomography (CT) imaging studies were performed in mice (four or five per group, depending on tumor growth) bearing subcutaneous and orthotopic MPM tumors by using HER1-and HER2-targeted indium 111 ( 111 In)-and iodine 125 ( 125 I)-labeled panitumumab and trastuzumab, respectively. Longitudinal MR imaging over 5 weeks was performed in three mice bearing orthotopic tumors to monitor tumor growth and metastases. SPECT/CT/MR imaging studies were performed at the final time point in the orthotopic models (n = 3). The standard unpaired Student t test was used to compare groups. Results:Orthotopic tumors and pleural effusions were clearly visualized at MR imaging 3 weeks after tumor cell inoculation. At 2 days after injection, the mean 111 In-panitumumab uptake of 29.6% injected dose (ID) per gram 6 2.2 (standard error of the mean) was significantly greater than the 111 In-trastuzumab uptake of 13.6% ID/g 6 1.0 and the 125 Ipanitumumab uptake of 7.4% ID/g 6 1.2 (P = .0006 and P = .0001, respectively). MR imaging fusion with SPECT/CT provided more accurate information about 111 In-panitumumab localization in the tumor, as the tumor was poorly visualized at CT alone. Conclusion:This study demonstrates the utility of radiolabeled anti-HER1 antibodies in the imaging of MPM in preclinical models.q RSNA, 2013 Supplemental material: http://radiology.rsna.org/lookup /suppl

show abstract

“…The incidence of MPM is rising, 1,2 and the prognosis is infaust; with the best standard of care, antifolate and platinum combination chemotherapy, overall survival is 13.3 months. 3 In the last ten years no major breakthroughs have been reported and consequently, this systemic therapy has remained unchanged.…”

Section: Introductionmentioning

confidence: 99%

“…4 Extensive investigation of the effects of implementation of radiotherapy and/or debulking surgery in standard treatment revealed variable success, but only when applied to select patient subgroups. 1,5–7 …”

Section: Introductionmentioning

confidence: 99%

Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy

et al. 2018

View full text Add to dashboard Cite

Rationale: Regulatory T cells (Treg) play a pivotal role in the immunosuppressive tumor micro-environment in cancer, including mesothelioma. Recently, the combination of autologous tumor lysate-pulsed dendritic cells (DC) and metronomic cyclophosphamide (mCTX) was reported as a feasible and well-tolerated treatment in malignant pleural mesothelioma patients and further as a method to reduce circulating Tregs.Objectives: The aim of this study was to establish the immunological effects of mCTX alone and in combination with DC-based immunotherapy on circulating Treg and other T cell subsets in mesothelioma patients.Methods: Ten patients received mCTX and DC-based immunotherapy after chemotherapy (n = 5) or chemotherapy and debulking surgery (n = 5). Peripheral blood mononuclear cells before, during and after treatment were analyzed for various Treg and other lymphocyte subsets by flow cytometry.Results: After one week treatment with mCTX, both activated FoxP3hi and naïve CD45RA+ Tregs were effectively decreased in all patients. In addition, a shift from naïve and central memory towards effector memory and effector T cells was observed. Survival analysis showed that overall Treg levels before treatment were not correlated with survival, however, nTreg levels before treatment were positively correlated with survival. After completion of mCTX and DC-based immunotherapy treatment, all cell subsets returned to baseline levels, except for the proportions of proliferating EM CD8 T cells, which increased.Conclusions: mCTX treatment effectively reduced the proportions of circulating Tregs, both aTregs and nTregs, thereby favoring EM T cell subsets in mesothelioma patients. Interestingly, baseline levels of nTregs were positively correlated to overall survival upon complete treatment.

show abstract

Malignant Pleural Mesothelioma

Cited by 33 publications

References 39 publications

Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe

Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe

Orthotopic Pleural Mesothelioma in Mice: SPECT/CT and MR Imaging with HER1- and HER2-targeted Radiolabeled Antibodies

Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy

Contact Info

Product

Resources

About